#RCUS↓

RCUS/ 10/13/2025 · 8:55 AM

Citi Raises Arcus Biosciences Price Target to $54 on Promising Cancer Drug Data

Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.

RCUS/ 10/06/2025 · 11:28 AM

Arcus Biosciences’ Casdatifan Drug Scores a 'Home Run'!

Casdatifan data is a "home run"! Survival without disease worsening hit 12 months, which is double the competitor's time.